into their constituent amino acids, with the highest specificity for carnosine (28, 29) . Both human genetic association studies and animal models suggest a pivotal role for the carnosinecarnosinase system in microvascular complications of diabetes (3, 19, 33, 34, 40) .
Genome-wide linkage scans and subsequent fine-mapping studies have indicated a strong association between a CTG trinucleotide repeat in CNDP1 and the susceptibility for developing diabetic nephropathy (14, 19, 26, 40) . More specifically, Caucasian type 2 diabeties (T2D) mellitus patients homozygous for the (CTG) 5 allele are less susceptible to develop diabetic nephropathy compared with T2D patients with a different genotype. In addition, it is known that homozygosis for the (CTG) 5 allele correlates with a significantly lower plasma carnosinase activity (12, 13, 19) . It has been hypothesized that low carnosinase activity might afford protection against diabetic nephropathy as a consequence of a higher availability of circulating carnosine upon dietary ingestion of carnosine from meat and fish (9, 13) .
Although formal proof for this assumption is still lacking in humans, studies in type 1 and 2 diabetic rodent models revealed that carnosine supplementation caused a later onset of hyperglycemia and a milder course of diabetes with significantly less renal damage (30, 31, 33, 34, 36) . This beneficial effect can be explained in part by carnosine's physiological and biochemical properties (9) . First, carnosine reduces glycoxidative stress, for example, by quenching reactive aldehydes and thereby preventing the formation of other reactive metabolites (3, 4, 11, 16, 24) . Second, carnosine may increase insulin secretion in rodent diabetic models (27, 34) , thereby improving glycemic control in these animals. Finally, carnosine supplementation in streptozotocin-induced diabetic and dyslipidemic Balb/cA mice reduces triglyceride and cholesterol levels in heart and liver (21) . The latter findings have been confirmed and extended in several other animal models of metabolic diseases (3, 23, 25) . Whether the protective effects of carnosine ingestion in rodents can be translated to humans is not known, because rodents, unlike humans, have no carnosinase in their plasma (18) . However, it can be expected that the normal dietary intake of carnosine in humans is more protective in people with low carnosinase activity. Carnosinase activity level is thought to be a stable, intrinsic characteristic of individuals. Therefore, a hypothesis of the current study is that T2D patients with low plasma carnosinase have a healthier lipid profile than T2D patients with high plasma carnosinase.
Although in the past decade the number of genetic studies on CNDP1 in relation to diabetic complications has increased, little attention has been given to actual plasma carnosinase activity and content levels in diabetic patients. In healthy subjects, sex, age, and particular polymorphisms of CNDP1 are known determinants of plasma carnosinase activity (12, 22, 29) . In one study with diabetic patients (type 1 and 2), carnosinase activity was increased compared with genotype-matched healthy controls (32) .
It has been established that prolonged aerobic exercise training could protect different diabetic rodent models against pathophysiological characteristics of diabetic nephropathy (17, 39) . Our laboratory recently demonstrated that elite athletes involved in high-intensity exercise have lower plasma carnosinase content (Ϫ31%) and activity (Ϫ17%) compared with untrained controls, raising the possibility that exercise training may reduce both the content and activity of the carnosinase enzyme (6) . In this light, we hypothesized that exercise training in diabetic patients, either directly or indirectly through lowering hyperglycemia, could decrease plasma carnosinase content and activity and thereby partly underlie the protective effects of exercise training on the development of diabetic complications.
For these purposes, we investigated both plasma carnosinase content and activity in a large cohort of males and females with T2D before and after a 6-mo intervention of exercise training (aerobic training only, resistance training only, and combined aerobic and resistance training) compared with sedentary controls.
METHODS
Plasma was taken from 243 T2D participants (153 males and 90 females, mean age ϭ 54.3 yr, SD ϭ 7.1) from the DARE (Diabetes Aerobic and Resistance Exercise) clinical trial (35) to measure plasma carnosinase content and activity before and after a 6-mo exercise training program. The DARE trial was designed originally to determine the effect of aerobic and resistance training alone (6 mo) vs. a sedentary control group and the incremental effects of performing both types of exercise (combined exercise training) vs. aerobic or resistance training alone on glycemic control and other risk factors for cardiovascular disease (35) . Initially, the DARE trial contained 251 patients, but samples of eight individuals were out of stock, leaving 243 subjects with plasma samples. The DARE trial design, participant characteristics, and intervention are briefly described below, and the reader is referred to Sigal et al. (35) for further details.
Design
A 26-wk, single-center, randomized controlled trial with parallelgroup design was performed. The trial included a 4-wk run-in phase plus a 22-wk intervention phase. Participants were randomly assigned to four groups: aerobic training, resistance training, combined aerobic and resistance training, or a control group. Before and after the 6-mo intervention period, heparinized plasma blood samples were taken in a fasted state, and participants were instructed not to exercise 48 h before each visit. The study was approved by the Ottawa Hospital Research Ethics Board, and all participants gave informed consent.
Participants
Baseline characteristics are presented in table 1. Inclusion criteria included type 2 diabetes [as defined by the American Diabetes Association (1)] for Ͼ6 mo and a baseline hemoglobin (Hb) A 1c value of 6.6 -9.9% (normal range, 4.0 -6.0%). Exclusion criteria were current insulin therapy, participation in exercise more than twice/wk for more than 20 min at a time during the previous 6 mo, changes during the previous 2 mo in oral hypoglycemic, antihypertensive, or lipid-lowering agents or body weight (Ն5%), a serum creatinine level of Ն200 mol/l (Ն2.26 mg/dl), proteinuria Ͼ1 g/day, blood pressure Ͼ160/95 mmHg, restrictions in physical activity because of disease, or the presence of other medical conditions that made participation inadvisable. The exercise intervention took place at eight communitybased exercise facilities in the Ottawa-Gatineau, ON, Canada, region. Exercise was supervised by personal trainers with equal frequency in all exercising groups. Individual exercise supervision was provided weekly for the first 4 wk after randomization, biweekly for the next 2 mo, and every 4 wk thereafter.
Intervention
Exercise group participants exercised three times weekly, and training progressed gradually in duration and intensity. The aerobic training group exercised on treadmills or bicycle ergometers. Participants progressed from 15 to 20 min/session at 60% of the maximum heart rate to 45 min/session at 75% of the maximum heart rate, as determined by using a maximal treadmill exercise test. Heart rate monitors (Polar Electro Oy, Kempele, Finland) displaying the participant's heart rate were used to standardize exercise intensity. Throughout the resistance training program, participants alternated between two groups of seven exercises performed on weight machines during each session, targeting all major muscle groups. These were as follows: group A: abdominal crunch, seated row, biceps curl, bench press, leg press, shoulder press, and leg extension; and group B: abdominal crunch, lateral pulldown, triceps pushdown, chest press, leg press, upright row, and leg curls. Participants performed two to three sets of each exercise at the maximum weight that could be lifted seven to nine times. When the participant could perform more than eight repetitions while maintaining proper form, the weight or the Patients on oral hypoglycemic agents n ϭ 49 n ϭ 49 n ϭ 47 n ϭ 40 Antihypertensive agents n ϭ 34 n ϭ 34 n ϭ 36 n ϭ 35 Lipid-lowering agents n ϭ 27 n ϭ 24 n ϭ 27 n ϭ 24
Values for BMI, age, duration of diabetes, and Hb A1c are means Ϯ SD. T2D, type 2 diabetes; BMI, body mass index.
resistance of the exercise was increased by 5-10 lbs. with guidance from the personal trainer. The combined exercise training group carried out the full aerobic training program plus the full resistance training program to ensure an adequate dose of each type of exercise. More details on the exercise training programs are available online (http://www.annals.org/cgi/content/full/147/6/357). Control participants were asked to revert to prestudy activity levels, had the same dietary intervention, and spent the same time with the research coordinator and dietitian as did the participants from the exercise groups.
Plasma Analyses
Glycemic control, lipid profile, and blood pressure. Hb A 1c was measured by turbidimetric immunoinhibition, and total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglyceride levels were measured using enzymatic methods on a Beckman-Coulter LX20 analyzer (Beckman Instruments, Brea, CA). Low-density lipoprotein cholesterol (LDL-C) levels were calculated using the Friedewald equation (15) . Blood pressure was measured after 10 min at rest; the mean of two readings obtained 2 min apart was used in statistical analysis.
Plasma carnosinase content and activity. Plasma carnosinase concentrations (content) were determined by a sandwich ELISA (enzyme-linked immunosorbent assay), as described in Adelmann et al. (2) . Plasma carnosinase activity was determined according to a method described by Teufel et al. (37) . Plasma carnosinase-specific activity was calculated by dividing carnosinase activity by its content (the activity of an enzyme per milligram of total protein) and expressed as mol·min Ϫ1 ·mg Ϫ1 .
Statistical Analysis
The effect of a 6-mo aerobic training, resistance training, or combined exercise training on plasma carnosinase content and activity was investigated by a linear mixed model design adjusted for sex, age, and body mass index (BMI). Within the mixed models, we calculated 95% confidence intervals and P values for prespecified intergroup Results are estimated means from linear mixed-effects models adjusted by age, sex, and BMI (baseline and 6-mo values are means Ϯ SE). CI, confidence interval; NA, not applicable. Neither carnosinase protein content nor its activity was influenced by the 6-mo exercise program, irrespective of the exercise training modality. Concerning plasma carnosinase content, the nos. of participants at 6 mo were 59, 49, 55, and 57 in the control group, the aerobic group, the resistance group, and the combined exercise training group, respectively. Concerning plasma carnosinase activity, the nos. of participants at 6 mo were 61, 57, 62, and 59 in the control group, the aerobic group, the resistance group, and the combined exercise training group, respectively. contrasts and for change in carnosinase and carnosinase activity within each group over time. For this model, SAS (version 9.2; SAS Institute, Cary, NC) was used. To investigate the intraindividual variation of plasma carnosinase content and activity over a 6-mo period, the intraclass correlation coefficient (ICC; a 2-way mixed model with measurements of absolute agreement) was calculated for control subjects (remaining sedentary) only. In addition, Pearson correlation coefficients were calculated to study the relationship between plasma carnosinase content and its activity within subjects at baseline. At baseline, the effect of age on plasma carnosinase content and activity was explored by linear regression analysis, with age as an independent variable and carnosinase as a dependent variable. In sensitivity analyses, duration of diabetes was taken as a covariate and analyzed for males and females separately. To study the effect of sex difference on plasma carnosinase, a two-sided independent-samples t-test was performed to compare plasma carnosinase content and activity between males and females at baseline. A linear regression analysis was performed to investigate the relationship between plasma carnosinase content/activity (independent variable) and glycemic control (Hb A 1c), the lipid profile (triglycerides, total cholesterol, HDL-C, LDL-C, and the total cholesterol/HDL-C ratio), and blood pressure (systolic and diastolic blood pressure) (dependent variables) at baseline. Patients with missing values at baseline (n ϭ 2 for plasma carnosinase content and n ϭ 4 for activity because of technical measurement errors) were excluded from the analyses. In sensitivity analyses, patients on glucose-, lipid-, and blood pressure-lowering medications were excluded while the relationship with Hb A 1c, lipid profile, and blood pressure, respectively, was investigated. In addition, age and sex were taken as covariates, and the natural logarithm of plasma carnosinase content and activity was used because distributions of the independent variables (plasma carnosinase content and activity) were skewed and normalized after logarithmic transformation. Standardized ␤-coefficients are reported. All analyses were done with SPSS statistical software (SPSS 20; SPSS, Chicago, IL), except for the linear mixed model design (as mentioned above). The statistical significance was set at P Ͻ 0.05. Table 2 provides the changes in plasma carnosinase protein content and activity by time and exercise training for 6 mo and adjusted by age, sex, and BMI. Neither carnosinase protein content nor its activity was influenced by the 6-mo exercise program, irrespective of exercise training modality (aerobic or resistance exercise alone or the combination of both types). At baseline, there was no association between Hb A 1c and plasma carnosinase protein content or activity in the overall population (Table 3) or when patients on glucose-lowering medication were excluded (n ϭ 58; B ϭ 0.13, P ϭ 0.328 for content; B ϭ 0.15, P ϭ 0.266 for activity). The aerobic and resistance training programs decreased Hb A 1c compared with the control group, and the combined training program did so to a greater extent than either aerobic or resistance training alone (preexercise Hb A 1c values: see Table 1 , postexercise values: control, 7.69%; aerobic, 7.23%; resistance, 7.47%; combined, 6.71%). In addition, fasting plasma glucose was only significantly decreased by the combined exercise training group (pre-and postexercise training values, respectively: control: 9.40 and 9.19, P ϭ 0.491; aerobic: 9.30 and 9.11, P ϭ 0.574; resistance: 9.33 and 8.79, P ϭ 0.096; combined: 9.11 and 7.88 mmol/l, P Ͻ 0.001).
RESULTS

Effect of Exercise Training and Glycemic Control on Plasma Carnosinase
We repeated all analyses above (effect of exercise training on plasma carnosinase and on glycemic control) separately for each sex, and all results were essentially identical (data not shown).
Test-Retest for Plasma Carnosinase Content and Activity
The ICCs for plasma carnosinase content (Fig. 1A) and activity (Fig. 1B) over a 6-mo period in the sedentary control A B C Fig. 1. A and B: the intraclass correlation coefficients (ICC) for plasma carnosinase content (A) and activity (B) over a 6-mo period in the sedentary control group are 0.91 (P Ͻ 0.001) and 0.63 (P Ͻ 0.001), respectively (line of identity is given). C: a low but significant positive correlation between plasma carnosinase content and activity at baseline for all participants (regression line is given). PRE and POST refer to pre-and post-intervention, respectively. group were 0.91 (P Ͻ 0.001) and 0.63 (P Ͻ 0.001), respectively, demonstrating an excellent stability for plasma carnosinase content but only a moderate stability for its activity. The lower and upper bounds of the 95% confidence interval (CI) for plasma carnosinase content were, respectively, 0.86 and 0.95 and 0.44 and 0.75 for carnosinase activity. In addition, a low but significant, positive correlation was observed between carnosinase content and activity at baseline for the entire group (r ϭ 0.22, P ϭ 0.001; Fig. 1C) .
Influence of Sex and Age on Plasma Carnosinase
Sex. At baseline, plasma carnosinase protein content was 32% higher in females compared with males, but there was no sex difference in carnosinase activity (Fig. 2A) . As a consequence, the specific activity of the enzyme was 24% higher in the males compared with the females (Fig. 2B) .
Age. Carnosinase protein content was negatively correlated with age in females (r ϭ Ϫ0.21, P ϭ 0.049) but not in males (r ϭ Ϫ0.12, P ϭ 0.132). Plasma carnosinase activity was negatively correlated with age for both males (r ϭ Ϫ0.19, P ϭ 0.022) and females (r ϭ Ϫ0.27, P ϭ 0.011).
Plasma Carnosinase, Lipid Profile, and Blood Pressure
At baseline, the ratio of total cholesterol to HDL-C was positively correlated with plasma carnosinase content (P Ͻ 0.01; Table 3 ). Carnosinase activity, on the other hand, was not associated with the total cholesterol/HDL-C ratio. In addition, HDL-C alone was negatively correlated with plasma carnosinase protein content (r ϭ Ϫ0.153, P ϭ 0.020) but positively correlated with activity (r ϭ 0.131, P ϭ 0.038). These effects appeared to be sex specific, as the correlations were predominantly present for males (carnosinase content: total cholesterol/HDL-C, r ϭ 0.239, P ϭ 0.002; HDL-C, r ϭ Ϫ0.168, P ϭ 0.039; carnosinase activity: HDL-C, r ϭ 0.271, P ϭ 0.001) but not for females. Finally, blood pressure and carnosinase protein content or activity were not correlated with one another. In sensitivity analyses, patients on lipid-and blood pressurelowering medication were excluded while the relationships with lipids (n ϭ 141) and blood pressure (n ϭ 105), respectively, were investigated. Here, no significant correlations were found between carnosinase content/activity and lipid levels or blood pressure. In addition, if these data were analyzed separately for males and females, low carnosinase content was associated with low total cholesterol/HDL-C ratio (B ϭ 0.22, P ϭ 0.048), and low carnosinase activity was associated with low HDL-C levels in males (B ϭ 0.26, P ϭ 0.020) but not in females.
DISCUSSION
Adults with T2D who are homozygous for the (CTG) 5 allele of CNDP1, encoding for low plasma carnosinase activity, have reduced risk of developing diabetic nephropathy (19, 26, 40) . In this study, the effect of exercise training or lowering hyperglycemia on plasma carnosinase content or activity was investigated. In addition, this large cohort of T2D adults, without advanced microvascular diabetic complications, was used to explore whether there was an association between carnosinase activity levels and other diabetes-related vascular risk factors, including dyslipidemia and increased blood pressure.
Effect of Exercise Training on Plasma Carnosinase
We hypothesized that exercise training (aerobic, resistance, or combined exercise) would reduce plasma carnosinase content and activity based on two previous observations. First, we recently reported lower plasma carnosinase levels (both content and activity) in elite athletes involved in high-intensity exercise training compared with untrained controls (6). Second, Riedl et al. (32) showed elevated plasma carnosinase activity, which was due to posttranslational modification of carnosinase, in diabetic patients. These reports suggested that exercise training might have a suppressive effect on carnosinase activity levels either directly or indirectly through improved glycemic control. This would be beneficial for people with diabetes, who tend to have higher plasma carnosinase levels than those without diabetes (32) . In the DARE trial, Hb A 1c decreased Ϫ0.51 and Ϫ0.38% in the aerobic and resistance training groups, respectively, compared with the control group. Moreover, combined exercise training resulted in additional changes in Hb A 1c of Ϫ0.46% compared with aerobic training alone and Ϫ0.59% compared with resistance training alone. However, we now show that exercise training, despite effectively reducing Hb A 1c , did not reduce plasma carnosinase content or activity. In addition, we did not observe a correlation between carnosinase content or activity and Hb A 1c at baseline (before the exercise intervention). Therefore, we refute the hypothesis that the protective effect of exercise training on the A B Fig. 2 . At baseline, plasma carnosinase protein content is higher in females compared with males, but there is no sex difference in carnosinase activity (A). As consequence, the specific activity of the enzyme is higher in the males compared with the females (B). *P Ͻ 0.001.
development of diabetic complications is partly explained by reducing plasma carnosinase, because 6-mo exercise training was unable to reduce carnosinase activity in T2D patients. Thus, there is an apparent discrepancy between the two observations. On the one hand, elite athletes involved in high-intensity exercise training had significantly lower plasma carnosinase content and activity (7); on the other hand, exercise training (aerobic, resistance, or combined training) did not influence plasma carnosinase in T2D adults (Table 2) . Recent twin data from our laboratory may provide a possible explanation for this discrepancy. Plasma carnosinase in monozygotic twins is highly correlated (r ϭ 0.93, P Ͻ 0.001 for content; and r ϭ 0.76, P Ͻ 0.001 for activity), but not in dizygotic twins (r ϭ 0.19, P ϭ 0.473 for content; and r ϭ 0.35, P ϭ 0.196 for activity) (unpublished data). This indicates that genetic factors may explain the high variability between healthy humans and the low variability within healthy humans. Thus, the difference between the elite athletes and the untrained (7) was likely due primarily to genetic factors rather than exercise training. However, it would be premature to exclude the possibility of a training effect in healthy subjects. Preliminary data from our laboratory show a decrease in carnosinase activity after a 5-wk sprint training program (3 times/wk, alternating cycling and running) in 10 healthy, previously untrained females (pre ϭ 7.2 Ϯ 0.3 mol·ml Ϫ1 ·h Ϫ1 , post ϭ 6.2 Ϯ 1.2 mol·ml Ϫ1 ·h Ϫ1 , P ϭ 0.04) but not in males (pre ϭ 6.3 Ϯ 1.8, post ϭ 5.8 Ϯ 0.7, P ϭ 0.38). These analyses were done retrospectively on the study of Baguet et al. (5) . It remains to be confirmed whether this training effect on plasma carnosinase activity is indeed present in healthy subjects. In addition, the exercise volume and intensity in the elite athletes were much higher than in the DARE trial. It is conceivable that, with much higher-volume and higher-intensity training, carnosinase content and activity could have been altered in type 2 diabetic individuals. However, to our knowledge there is no physiological intervention that can acutely or even subacutely alter plasma carnosinase content and activity.
Effect of Sex and Age on Plasma Carnosinase
Similarly to healthy individuals, plasma carnosinase content and activity displayed a very large interindividual variability in T2D individuals (range content: 22-211 g/ml; range activity: 2-10 g/ml). Yet within the T2D subjects the variability over a 6-mo period (evaluated in the sedentary controls) was very small, especially for carnosinase content (ICC ϭ 0.91) and to a lesser extent for activity (ICC ϭ 0.63). Sex and age are two known determinants of plasma carnosinase in healthy subjects (8, 12, 22, 29) . It is worthy to mention that plasma carnosinase behaves slightly differently in individuals with diabetes. Similar to healthy subjects, diabetic females in the present study had higher carnosinase content levels compared with males. In nondiabetic individuals, this sex difference is also present for carnosinase activity, but in our present sample of diabetic individuals, the activity level was equal between T2D males and females. As a consequence, the specific activity of the enzyme was lower for the diabetic females than for the diabetic males, suggesting that an unknown factor was suppressing plasma carnosinase activity in T2D females. Lower carnosinase activity might to some extent protect diabetic females from developing diabetic nephropathy. Indeed, Kamenov et al. (20) showed that diabetic nephropathy develops earlier in males than in females with T2D. In the present study, we found for the first time a negative correlation between age and carnosinase activity (males: r ϭ Ϫ0.19, P ϭ 0.022; females: r ϭ Ϫ0.27, P ϭ 0.011), even if duration of diabetes was adjusted for. However, our study contained middle-aged and older (age range: 39 -70 yr) T2D individuals, in contrast to previous studies with younger (Յ50 yr) healthy subjects.
Low Plasma Carnosinase Content/Activity Associated With Lipid Profile and Blood Pressure?
Several studies in rodents have recently reported protective effects of carnosine administration on dyslipidemia [lipid profile in plasma (3, 25) , cholesterol levels in heart and liver (21, 25) , atherosclerosis (23) ] and blood pressure (3) . In contrast to rodents, humans have the enzyme plasma carnosinase, and as we confirm in this study, its activity is highly variable between individuals. We hypothesized that diabetic patients with the lowest plasma carnosinase levels would have the highest circulating carnosine levels upon dietary ingestion of carnosine (present in meat and fish), and therefore, they would have the most healthy lipid profiles. However, the observed correlations did not support the hypothesis.
Conclusion
We found high interindividual but low intraindividual variability in plasma carnosinase content and activity over a 6-mo period in our group of middle-aged and older adults with T2D. Low plasma carnosinase activity was not associated with a more favorable lipid profile. The effects of different exercise training modalities and hyperglycemia (as assessed by Hb A 1c ) were investigated, but no relationship with plasma carnosinase was found. Our study could not confirm the hypothesis that the protective effect of exercise training on development of diabetic complications is somehow related to a training-induced attenuation of plasma carnosinase. 
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